PacBio cuts outlook, delays breakeven, but new products and partnerships lift shares
PacBio slashes 2026 revenue guidance and pushes cash-flow breakeven to 2028 PacBio cut its 2026 revenue forecast to $155–$165 million and now expects cash-flow breakeven in 2028, a year later than planned. The SPRQ-Nx chemistry transition is slower than expected, and instrument demand is weak. This makes the company's path to profitability longer and riskier, pressuring the stock.
This is the main negative force this period, directly lowering revenue expectations and delaying profitability.
New SPRQ-Nx chemistry boosts output and cuts costs for Vega system PacBio announced SPRQ-Nx chemistry and a software update for its Vega sequencer, increasing data output by 50% and cutting cost per gigabase by about 40%. It also adds multiomic capabilities and compliance features. This should make PacBio's products more competitive and attractive to customers, supporting future sales.
This is a new product improvement that could drive future demand and offset some of the negative guidance.
EpiSign-Geneyx partnership incorporates PacBio HiFi sequencing for rare disease analysis EpiSign and Geneyx announced a partnership to integrate genomic and epigenomic analysis for rare diseases, using PacBio HiFi sequencing data. This expands the use of PacBio's platform in clinical research and could lead to more sales. The stock jumped 9.9% on the news, hitting a new 52-week high.
This is a new partnership that directly involves PacBio's technology and drove a significant stock move.
Sampled wins VA contract using PacBio Revio systems Genomics provider Sampled announced a five-year contract worth up to $27.1 million from the U.S. Department of Veterans Affairs to support research using PacBio Revio sequencing systems. This validates PacBio's technology in a large government research setting and could lead to more orders. The stock rose 5.8% on the day.
This is a new contract that directly benefits PacBio by increasing demand for its Revio systems.